Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1971 2
1972 8
1973 9
1974 9
1975 20
1976 11
1977 10
1978 13
1979 14
1980 14
1981 13
1982 22
1983 8
1984 24
1985 22
1986 14
1987 22
1988 21
1989 26
1990 31
1991 20
1992 23
1993 14
1994 22
1995 28
1996 20
1997 31
1998 25
1999 22
2000 18
2001 19
2002 22
2003 22
2004 30
2005 25
2006 24
2007 32
2008 38
2009 52
2010 63
2011 74
2012 119
2013 166
2014 204
2015 255
2016 265
2017 303
2018 327
2019 428
2020 555
2021 602
2022 624
2023 707
2024 727
2025 808
2026 454

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,539 results

Results by year

Filters applied: . Clear all
Page 1
Comparing transcranial magnetic stimulation and esketamine treatment response trajectories in resistant depression.
Benster LL, Kohn JN, Wade B, Stapper N, Weissman CR, Miron JP, Daskalakis ZJ, Appelbaum LG. Benster LL, et al. J Affect Disord. 2026 Jun 7:122107. doi: 10.1016/j.jad.2026.122107. Online ahead of print. J Affect Disord. 2026. PMID: 42259490
OBJECTIVE: Repetitive transcranial magnetic stimulation (rTMS) and intranasal esketamine are FDA-approved for treatment-resistant depression (TRD), yet comparative real-world data on response trajectories and predictors of outcomes remain limited. ...No significant …
OBJECTIVE: Repetitive transcranial magnetic stimulation (rTMS) and intranasal esketamine are FDA-approved for treatment-resistant …
Direct and indirect associations linking COVID-19 severity to internalizing disorders and symptoms among participants in New Haven, CT.
Davtian D, Qiu D, Cabrera-Mendoza B, Nunez YZ, Krystal JH, Pietrzak RH, Gelernter J, Polimanti R. Davtian D, et al. J Affect Disord. 2026 Jun 7:122082. doi: 10.1016/j.jad.2026.122082. Online ahead of print. J Affect Disord. 2026. PMID: 42259487
Leveraging the PsychGenCOV19 cohort including 1132 participants enrolled in New Haven, CT, we observed that moderate COVID-19 severity was associated with greater odds of internalizing disorders (major depressive disorder, MDD OR = 3.74; generalized anxiety disor …
Leveraging the PsychGenCOV19 cohort including 1132 participants enrolled in New Haven, CT, we observed that moderate COVID-19 severity was a …
From Psychache to Neuroplasticity: A Unified Rescue-Repair Model of Ketamine's Anti-Suicidal Action.
Domany Y, Solomon A. Domany Y, et al. Neurosci Biobehav Rev. 2026 Jun 7:106804. doi: 10.1016/j.neubiorev.2026.106804. Online ahead of print. Neurosci Biobehav Rev. 2026. PMID: 42259434 Review.
We propose the Unified Rescue-Repair Model of Ketamine's Anti-Suicidal Action: a two-phase integrative reading. The first phase, an acute rescue, opens within minutes: a glutamatergic surge silences the lateral habenula, transiently disrupts default-mode and salienc …
We propose the Unified Rescue-Repair Model of Ketamine's Anti-Suicidal Action: a two-phase integrative reading. The first phas …
[Intravenous Subnarcotic Ketamine Infusions for Treatment-Resistant Depression: Historical Development, Comparison with Esketamine Nasalspray, and Prospects].
Bonnet U, Scherbaum N, Juckel G, Bschor T. Bonnet U, et al. Fortschr Neurol Psychiatr. 2026 Jun 8. doi: 10.1055/a-2846-4275. Online ahead of print. Fortschr Neurol Psychiatr. 2026. PMID: 42259381 German.
INTRODUCTION: Esketamine nasal spray (EN) has been approved in Germany since 2021 for the treatment of treatment-resistant depression (TRD). ...Selective literature search in PubMed for clinical studies comparing SKI and EN for TRD. International guidelines for d …
INTRODUCTION: Esketamine nasal spray (EN) has been approved in Germany since 2021 for the treatment of treatment-resistant depress …
Role of accumbens medium spiny neurons subtypes in reinstatement to ketamine cues in male and female Long Evans rats.
Hagarty DP, Dawoud A, Guerrero AB, Etienne K, Jennings SD, Martinez K, Csernecky O, Schoepfer KJ, Strong CE, Saland SK, Kabbaj M. Hagarty DP, et al. Neuropharmacology. 2026 Jun 6;298:111067. doi: 10.1016/j.neuropharm.2026.111067. Online ahead of print. Neuropharmacology. 2026. PMID: 42252079
Ketamine, a non-competitive N-Methyl-D-Aspartate receptor antagonist, was approved for use with Treatment-Resistant Depression (TRD) and is currently in clinical trials for treating substance use disorder (SUD), and Post Traumatic Stress Disorder. Howe …
Ketamine, a non-competitive N-Methyl-D-Aspartate receptor antagonist, was approved for use with Treatment-Resistant Depression …
Effect of intraoperative ketamine on pain, opioid use, and psychological recovery in orthopedic trauma patients (KOPM trial): protocol for a randomized, single-blind trial.
Curran C, Hernandez EJ, Hudnall J, Sra J, Davis ME. Curran C, et al. Pain Manag. 2026 Jun 6:1-10. doi: 10.1080/17581869.2026.2682470. Online ahead of print. Pain Manag. 2026. PMID: 42251276
BACKGROUND: Orthopedic trauma patients frequently struggle with pain control, prolonged opioid use, and psychiatric co-morbidities, including depression and post-traumatic stress disorder (PTSD). Current treatment strategies inadequately address both pain and psycho …
BACKGROUND: Orthopedic trauma patients frequently struggle with pain control, prolonged opioid use, and psychiatric co-morbidities, includin …
Esketamine alleviates trigeminal neuralgia and anxiety-like behaviors in mice by inhibiting RIPK1/RIPK3/MLKL-mediated necroptosis.
Dong R, Liu J, Shen Y, Wei M, Liu J, Liu P, Liu X, Zhao S, Wang X. Dong R, et al. Brain Res Bull. 2026 Jun 5:111987. doi: 10.1016/j.brainresbull.2026.111987. Online ahead of print. Brain Res Bull. 2026. PMID: 42250657 Free article.
BACKGROUND: Trigeminal neuralgia (TN) is a debilitating orofacial pain condition frequently complicated by anxiety and depression, forming a self-reinforcing pain-affect cycle with limited therapeutic options. METHODS: A TN mouse model with anxiety-like behavior was establ …
BACKGROUND: Trigeminal neuralgia (TN) is a debilitating orofacial pain condition frequently complicated by anxiety and depression, fo …
The effect of treatments for postpartum depression on breastfeeding practices: a systematic review and meta-analysis.
Shen S, Wang B, Zhao Y, Ali S, Smith RD. Shen S, et al. Midwifery. 2026 Jun 1;160:104885. doi: 10.1016/j.midw.2026.104885. Online ahead of print. Midwifery. 2026. PMID: 42248094 Review.
BACKGROUND: Breast milk provides unique health benefits for infants, mothers and supports mother-infant bonding. Postpartum depression (PPD) is prevalent, affecting up to 25% of mothers. Mothers with PPD are less likely to breastfeed than mothers without PPD. Despite the e …
BACKGROUND: Breast milk provides unique health benefits for infants, mothers and supports mother-infant bonding. Postpartum depression …
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".
Reif A, Anıl Yağcıoğlu AE, Bitter I, Buyze J, Frey R, Fu DJ, Godinov Y, Haggström L, Kambarov Y, Nielsen RE, Oliveira-Maia AJ, von Holt C, Young AH, Cubała WJ. Reif A, et al. Eur Neuropsychopharmacol. 2026 Jun 5;112:112885. doi: 10.1016/j.euroneuro.2026.112885. Online ahead of print. Eur Neuropsychopharmacol. 2026. PMID: 42247854 No abstract available.
Association of multimodal analgesic protocol with postpartum depression incidence and sleep quality in high-risk parturients.
Zhang H, Jiang YA, Fu H, Zhang L, Zhang G. Zhang H, et al. Front Med (Lausanne). 2026 May 20;13:1828838. doi: 10.3389/fmed.2026.1828838. eCollection 2026. Front Med (Lausanne). 2026. PMID: 42245962 Free PMC article.
METHODS: This single-center, retrospective cohort study included 82 high-risk parturients who received intraoperative esketamine (0.25 mg/kg) followed by postoperative dexmedetomidine-esketamine patient-controlled analgesia for 48 h between January 2023 and December …
METHODS: This single-center, retrospective cohort study included 82 high-risk parturients who received intraoperative esketamine (0.2 …
6,539 results